Sanofi
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SNYNF research report →
Companywww.sanofi.com
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
- CEO
- Olivier Charmeil
- IPO
- 2008
- Employees
- 82,878
- HQ
- Paris, FR
Price Chart
Valuation
- Market Cap
- $106.53B
- P/E
- 8.91
- P/S
- 1.56
- P/B
- 1.27
- EV/EBITDA
- 9.78
- Div Yield
- 5.37%
Profitability
- Gross Margin
- 71.62%
- Op Margin
- 25.09%
- Net Margin
- 17.59%
- ROE
- 14.41%
- ROIC
- 11.66%
Growth & Income
- Revenue
- $43.61B · -1.53%
- Net Income
- $7.81B · 40.47%
- EPS
- $6.40 · 43.82%
- Op Income
- $14.25B
- FCF YoY
- 52.64%
Performance & Tape
- 52W High
- $107.24
- 52W Low
- $83.17
- 50D MA
- $90.57
- 200D MA
- $95.06
- Beta
- 0.28
- Avg Volume
- 4.65K
Get TickerSpark's AI analysis on SNYNF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 10, 14 | Sanofi | buy | 17,286 |
| Jul 10, 14 | Sanofi | buy | 18,057 |
| Jul 10, 14 | Sanofi | buy | 20,638 |
| Jul 10, 14 | Sanofi | buy | 15,815 |
| Jul 10, 14 | Sanofi | buy | 53,994 |
| Jul 10, 14 | Sanofi | buy | 26,891 |
| Jul 10, 14 | Sanofi | buy | 17,347 |
| Jul 10, 14 | Sanofi | buy | 2,502 |
| Jul 10, 14 | Sanofi | buy | 2,470 |
Our SNYNF Coverage
We haven't published any research on SNYNF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SNYNF Report →